首页> 美国卫生研究院文献>Pharmaceutics >Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses
【2h】

Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses

机译:用胃肠道模拟器(GIS)和沉淀途径分析探索右旋布洛芬对乙酰氨基酚药品的生物等效性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present work aimed to explain the differences in oral performance in fasted humans who were categorized into groups based on the three different drug product formulations of dexketoprofen trometamol (DKT) salt—Using a combination of in vitro techniques and pharmacokinetic analysis. The non-bioequivalence (non-BE) tablet group achieved higher plasma Cmax and area under the curve (AUC) than the reference and BE tablets groups, with only one difference in tablet composition, which was the presence of calcium monohydrogen phosphate, an alkalinizing excipient, in the tablet core of the non-BE formulation. Concentration profiles determined using a gastrointestinal simulator (GIS) apparatus designed with 0.01 N hydrochloric acid and 34 mM sodium chloride as the gastric medium and fasted state simulated intestinal fluids (FaSSIF-v1) as the intestinal medium showed a faster rate and a higher extent of dissolution of the non-BE product compared to the BE and reference products. These in vitro profiles mirrored the fraction doses absorbed in vivo obtained from deconvoluted plasma concentration–time profiles. However, when sodium chloride was not included in the gastric medium and phosphate buffer without bile salts and phospholipids were used as the intestinal medium, the three products exhibited nearly identical concentration profiles. Microscopic examination of DKT salt dissolution in the gastric medium containing sodium chloride identified that when calcium phosphate was present, the DKT dissolved without conversion to the less soluble free acid, which was consistent with the higher drug exposure of the non-BE formulation. In the absence of calcium phosphate, however, dexketoprofen trometamol salt dissolution began with a nano-phase formation that grew to a liquid–liquid phase separation (LLPS) and formed the less soluble free acid crystals. This phenomenon was dependent on the salt/excipient concentrations and the presence of free acid crystals in the salt phase. This work demonstrated the importance of excipients and purity of salt phase on the evolution and rate of salt disproportionation pathways. Moreover, the presented data clearly showed the usefulness of the GIS apparatus as a discriminating tool that could highlight the differences in formulation behavior when utilizing physiologically-relevant media and experimental conditions in combination with microscopy imaging.
机译:本研究的目的是结合体外技术和药代动力学分析,根据右旋苯丙酸丁三醇(DKT)盐的三种不同药物制剂,对在禁食的人群中口服性能的差异进行解释。非生物等效性(non-BE)片剂组的血浆Cmax和曲线下面积(AUC)比参考和BE片剂组高,片剂组成仅有一个差异,那就是磷酸一氢钙的存在非BE制剂的片剂核心中的赋形剂。使用设计为0.01 N盐酸和34 mM氯化钠作为胃介质并以禁食状态的模拟肠液(FaSSIF-v1)作为肠介质的胃肠道模拟器(GIS)设备确定的浓度曲线显示出更快的速度和更高的程度与BE和参考产品相比,非BE产品的溶出度更高。这些体外曲线反映了从去卷积血浆浓度-时间曲线中获得的体内吸收剂量分数。但是,当胃介质中不包括氯化钠,而无胆盐和磷脂的磷酸盐缓冲液被用作肠道介质时,这三种产品的浓度曲线几乎相同。在含氯化钠的胃介质中对DKT盐溶解的显微镜检查表明,当存在磷酸钙时,DKT溶解而未转化为难溶的游离酸,这与非BE制剂的较高药物暴露相符。然而,在不存在磷酸钙的情况下,右酮洛芬的丁苯三胺盐溶解开始于纳米相的形成,该相逐渐发展为液相-液相分离(LLPS),并形成了溶解性较低的游离酸晶体。这种现象取决于盐/赋形剂的浓度以及盐相中游离酸晶体的存在。这项工作证明了赋形剂和盐相纯度对盐歧化途径的演化和速率的重要性。此外,所提供的数据清楚地表明了GIS设备作为一种区分工具的有用性,该工具可以在与生理学相关的介质和实验条件与显微镜成像结合使用时突出配方行为的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号